Admet For Medicinal Chemists: A Practical Guide

The acronym stands for absorption, distribution, metabolism, excretion, and toxicity. They, along with efficacy, are critical properties in determining whether a new molecular entity will become a clinical candidate and subsequently, another drug on the market. ADMET can also stand for the process of determining the properties, or the discipline that focuses on that process. Contributors from European and US drug companies, along with a university here and there, explain how to determine the properties and translate the measurements into predictions for commercial success. Among their topics are pharmacokinetics for medicinal chemists, in vitro approaches to genetic toxicity, preclinical candidate nomination and development, and fragment-based drug design. Annotation c2011 Book News, Inc., Portland, OR (booknews.com)

KATYA TSAIOUN, PhD, is Chief Scientific Officer of Cyprotex and, previously, president and founder Apredica, which was acquired by Cyprotex. Both companies specialize in the rapid preclinical in vitro assessment of the ADME-Tox (Absorption, Distribution, Metabolism, Elimination, and Toxicity) properties of small-molecule and peptide therapeutics.

STEVEN A. KATES, PhD is Vice President of Research and Development at Ischemix. He is a highly experienced chemist with over twenty years in R&D for both life science products and human therapeutics, and has advanced several compounds through drug development from early preclinical to early clinical development. He has more than 100 patents and publications, including one book.